NorthStar Medical Radioisotopes LLC
RELATED CONTENT
April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...
April 16, 2021 
March 16, 2021 — NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its ...
March 16, 2021
March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...
March 08, 2021
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of ...
February 18, 2020
NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The agreement comes as part of an industry outreach initiative to establish reliable domestic molybdenum-99 (Mo-99) production without the use of highly enriched uranium.
July 26, 2019
NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-99) processing facility in Beloit, Wis., with equipment installation currently underway. Establishing this processing facility is part of NorthStar’s staged development and dual processing pathway approach to expanding current capacity and efficiencies in Mo-99 production.
July 16, 2019
February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...
February 08, 2018
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) for its accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The addition brings the total funding for the new method, in development by subisidiary NorthStar Medical Radioisotopes, to $11.1 million.
January 17, 2017
NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Mo.
May 13, 2016
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
September 11, 2015